ACRES Commercial Realty Corp. ACR
8.10 USD -0.30 (-3.57%)
Regular-session close
8.10 0.00 0.00%
After hours · Nov 20, 4:01 PM ET
8.00 Day range 8.53
7.76 52-week range 24.61
- YTD
- -62.04%
- 1 year
- -59.05%
News
globenewswire.com Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy Updated safety data of 36 patients treated with FT819 across three regimens and four autoimmune disease indications with no dose-limiting toxicities continues to be favorable 100% (3 of 3) of…
globenewswire.com Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout NEK7-directed molecular glue degrader inhibited NLRP3 inflammasome activation in human experimental systems and demonstrated anti-inflammatory activity in a rabbit model of gouty arthritis GEMINI-1,…
globenewswire.com ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure BRUSSELS and CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced further data characterizing the clinical profile of…
globenewswire.com IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses SYDNEY, AUSTRALIA, Nov. 08, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune…
globenewswire.com Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026 Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses
globenewswire.com Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases 100% (6 of 6) of dermatomyositis patients maintained immunomodulator-free, moderate-to-major TIS responses through one year, with most patients also free of steroids
seekingalpha.com ACRES Commercial Realty Corp. (ACR) Q3 2026 Earnings Call Transcript ACRES Commercial Realty Corp. ( ACR ) Q3 2026 Earnings Call November 5, 2026 10:00 AM EST Company Participants Kyle Brengel - Chief Operating Officer Andrew Fentress - Chairman of the Board & MD of…
globenewswire.com argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM population First Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an…
marketbeat.com What ACRES Commercial Realty (ACR) Said on Its Q3 Earnings Call ACRES Commercial Realty NYSE: ACR reported a third-quarter loss as it absorbed transaction-related charges following its merger and internalization, while executives outlined plans to grow earnings…
globenewswire.com Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB Asset acquisition establishes immunology and inflammation (I&I) as a strategic pillar alongside oncology, extending the company into autoimmune disease
prnewswire.com Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity Pivotal results from the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed retatrutide delivered substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some…
zacks.com ACRES Commercial (ACR) Reports Q3 Loss, Tops Revenue Estimates ACRES Commercial (ACR) came out with a quarterly loss of $2.64 per share versus the Zacks Consensus Estimate of $0.15. This compares to earnings of $1.01 per share a year ago.
prnewswire.com ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR THIRD QUARTER 2026 UNIONDALE, N.Y., Nov. 4, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp.
defenseworld.net ACRES Commercial Realty (ACR) Set to Announce Quarterly Earnings on Wednesday ACRES Commercial Realty (NYSE: ACR - Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of…
businesswire.com KBRA Publishes Ratings for ACRES Commercial Realty Corp. NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA publishes the issuer rating of BB, senior secured debt rating of BBB-, and preferred stock rating of BB- for ACRES Commercial Realty Corp. (NYSE:…
globenewswire.com Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium Timothy A. Yap, MBBS, Ph.D., FRCP, of The University of Texas MD Anderson Cancer Center to present results from the dose escalation phase of the ACR-2316 Phase 1/2 trial on November 20, 2026 Durable…benzinga.com Citizens Maintains Market Outperform on ACRES Commercial Realty, Lowers Price Target to $17 Citizens analyst Chris Muller maintains ACRES Commercial Realty (NYSE:ACR) with a Market Outperform and lowers the price target from $23 to $17.
prnewswire.com ACRES Commercial Realty Corp. to Report Results for Third Quarter 2026 UNIONDALE, N.Y., Oct. 21, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company" or "ACRES") announced today that it will release its results for the third quarter 2026 on…
globenewswire.com Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027 ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models Prioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent…
globenewswire.com CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company's Phase 1 clinical data of its…
globenewswire.com Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026 Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with…
